A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

2017126 citationsJournal Articlehybrid Open Access

Authors

NCT01706926; results.

Published in: Annals of the Rheumatic Diseases

Volume 76, Issue 6, pp. 1020-1030

Field-Weighted Citation Impact: 16.13